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ABSTRACT
The use of chemically synthesized short interfering
RNAs (siRNAs) is currently the method of choice
to manipulate gene expression in mammalian cell
culture, yet improvements of siRNA design is
expectably required for successful application
in vivo. Several studies have aimed at improving
siRNA performance through the introduction of
chemical modifications but a direct comparison of
these results is difficult. We have directly compared
the effect of 21 types of chemical modifications
on siRNA activity and toxicity in a total of 2160
siRNA duplexes. We demonstrate that siRNA activity
is primarily enhanced by favouring the incorporation
of the intended antisense strand during RNA-
induced silencing complex (RISC) loading by modu-
lation of siRNA thermodynamic asymmetry and
engineering of siRNA 3’-overhangs. Collectively,
our results provide unique insights into the tole-
rance for chemical modifications and provide a
simple guide to successful chemical modification
of siRNAs with improved activity, stability and low
toxicity.
INTRODUCTION
The use of RNA interference (RNAi)-based strategies has
recently become the technique of choice to silence gene
expression in mammalian cell culture. In typical strategies,
21-bp dsRNA molecules, termed short interfering RNAs
(siRNAs), with perfect complementarity to the target
RNA are used as experimental triggers of RNAi (1).
Upon delivery into the cell, siRNAs are incorporated
into the RNA-induced silencing complex (RISC) contain-
ing the signature component of the RNAi machinery,
Argonaute 2 (Ago2) (2–4). The siRNA strand containing
the thermodynamically less stable 50-end is preferentially
incorporated as the guiding strand of RISC (5,6), while
the non-guiding sense strand (SS) of the siRNA duplex is
cleaved by Ago2 and liberated (7–9). This generates the
activated RISC
  containing the guiding antisense strand
(AS), which binds the complementary target RNAs and
leads to their cleavage by Ago2 (10). Whereas unmodiﬁed
siRNAs are highly eﬃcient in cell culture, chemical
*To whom correspondence should be addressed. Tel: +45 8942 2668; Fax: +45 8619 6500; Email: jebb@mb.au.dk
 2009 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.modiﬁcation is generally considered a prerequisite for ful-
ﬁlling the potential of siRNAs in vivo and indeed success-
ful experiments in animal models have relied on injection
of chemically modiﬁed siRNAs (11–13). In particular, the
half-life of unmodiﬁed siRNAs in vivo is in the range
of minutes, but this can be signiﬁcantly improved by
chemical modiﬁcations, albeit often at the price of
reduced siRNA activity (14–18). In addition, chemical
modiﬁcation of siRNAs may be required for delivery stra-
tegies, e.g. by conjugation to lipids (11,19), membrane-
penetrating peptides (20) or RNA aptamer sequences
(21). Furthermore, modiﬁed siRNAs with superior
potency will reduce the dose required for gene silencing
(14,22,23), and speciﬁc chemical modiﬁcations can mini-
mize siRNA side-eﬀects, such as the induction of recipient
immune responses and inherent oﬀ-targeting eﬀects
(24–26). Therefore, a primary objective in the optimiza-
tion of siRNA performance through chemical modiﬁca-
tion is to identify the type and position of speciﬁc
alterations that can be introduced without compromising
siRNA activity. A direct comparison of the various che-
mistries used for siRNA optimization is currently ham-
pered by the fact that existing studies evaluate isolated
chemistries in a variety of assays and sequence contexts.
In addition, multiple chemistries are rarely included in the
same siRNA duplex rendering identiﬁcation of positive or
negative synergy impossible.
In this study, we have made a direct comparison of the
impact of 21 diﬀerent types of chemical modiﬁcations on
siRNA eﬃciency and cell viability using a total of 2160
siRNAs. The results from this extensive screen provide
important insights into where and how siRNA strands
can be modiﬁed by particular chemistries and how che-
mistries can be combined; moreover it allows us to formu-
late design rules to create superior siRNAs in terms of
activity, stability and toxicity.
MATERIALS AND METHODS
Cellculture
HeLa cells stably expressing eGFP (HeLa-eGFP) were
obtained by transfection with pEGFP-C1 (Clontech
Laboratories, USA). A clone of the transfected pool was
derived by G418 selection and cultivated in D-MEM
(GIBCO-Invitrogen Corporation, USA) containing 10%
FBS (foetal bovine serum) and 1% penicillin/streptomy-
cin. The human lung cancer cell line H1299 was grown
in RPMI-1640 (GIBCO) containing 10% FBS and 1%
penicillin/streptomycin.
Synthesis of oligonucleotides
The phosphoramidites were incorporated into the siRNA
sequence through solid-phase DNA/RNA synthesis (27)
on an automated DNA/RNA synthesizer (for structures of
chemically modiﬁed nucleotide monomers, see Figure 1).
For a standard RNA synthesis cycle (1–5mmol scale),
O20-TBDMS protected RNA phosphoramidites and
common reagents were used and the stepwise coupling
yield of all monomers was >99%. For incorporation of
modiﬁed nucleotides, a coupling time of 10min was used.
Following standard deprotection, puriﬁcation and work-
up, the composition and purity (>80%) of the resulting
oligonucleotides was conﬁrmed by MALDI-MS analysis
and ion exchange HPLC. UNA (unlocked nucleic acid),
LNA (locked nucleic acid) and ALN (a-L-LNA) modiﬁed
oligonucleotides were obtained by using commercially
available UNA (www.ribotask.com), LNA (www.exiqon.
com) and a-L-LNA (www.exiqon.com). The UNA phos-
phoramidites were synthesized as O20-TBDMS derivatives
by an optimized version of the published procedure
for synthesis of the thymine monomer (28). The chemical
synthesis of the remaining modiﬁed phosphoramidites is
previously described; HM (40-C-hydroxymethyl-DNA)
(29), ADA (20-N-adamantylmethylcarbonyl-20-amino-
LNA) (Babu, B.W. et al., Manuscript in preparation),
PYR (20-N-pyren-1-ylmethyl-20-amino-LNA) (30),
EA (20-aminoethyl), GE (20-guanidinoethyl), CE
(20-cyanoethyl) (31,32), AP (20-aminopropyl) (33), OX
(oxetane-LNA) [(34) and references therein], CLNA
(20,40-carbocyclic-LNA-locked nucleic acid), CENA
(20,40-carbocyclic-ENA-locked nucleic acid) (35),
AENA (20-deoxy-20-N,40-C-ethylene-LNA) (36), OMe
(20-O-methyl), F (20-ﬂuoro) (22), ANA (altritol nucleic
acid) (37), HNA (hexitol nucleic acid) (38), AEM
(20-aminoethoxymethyl) and APM (20-aminopropoxy-
methyl) (39).
Evaluation of siRNA effecton eGFP expression
and cell viability
A library of 2160 siRNAs was derived by annealing 48
ASs and 45 SSs in Tris–Borate–EDTA buﬀer (Ambion
Applied Biosystem Inc., USA) by heating to 908C for
2min and slow cooling to 258C for 45min using a Gene
Amp-R PCR System 9700 termocycler (Applied
Biosystems, USA). HeLa-eGFP were plated in a
384-well format in 50ml complete medium 24h prior to
transfection with 10nM siRNAs (ﬁnal concentration)
complexed with 0.17ml INTERFERin/50ml medium
(Polyplus-transfection SA, France) using an auto-
mated robotic platform (EVO-Freedom, TECAN Ltd,
Switzerland). Cells were ﬁxed 72h post-transfection with
3.7% paraformaldehyde (PFA) and stained with a mix of
4,6-diamidino-2-phenylindole (DAPI) and Sytoblue 42 for
nuclear and cytosolic counter-stain and imaged using an
automated confocal microscope (Opera, PerkinElmer
Cellular Technologies Germany GmbH) equipped with a
20  water immersion objective. Images were analysed in a
blind manner using automated image analysis software
acquiring 10 ﬁelds per well corresponding to  1000 cells
(Acapella, PerkinElmer Cellular Technologies Germany
GmbH). Cell number, nuclei size and eGFP intensity
data were analysed using the R-Project statistical package
(40). The eGFP intensity threshold was calculated by
taking the mean of the values detected in the positive
controls in each plate plus three times the standard devi-
ation; eGFP values below this threshold point were
considered as eGFP down-regulation. The results repre-
sent average values from triplicate assays repeated twice.
eGFP expression was normalized to cells transfected with
siEGFP mismatch control (Dharmacon-, Dharmacon,
2868 Nucleic Acids Research, 2009, Vol. 37,No. 9Inc.) and cell viability was normalized to cells treated with
transfection reagent alone.
siRNA stability assay
Annealed siRNAs were incubated at 378C in 80% FBS in
D-MEM (Gibco) for the indicated time. Aliquots of 5ml
(each containing 20pmol of siRNA) were diluted in 25ml
1.2  TBE loading buﬀer (1.2  TBE, 10% glycerol, brom-
phenol blue) and snap frozen on dry ice. Samples were run
on a 6% agarose gel and stained using SYBR Gold
(Invitrogen).
Dual-luciferase assay
The reporter constructs pISOAS-target and pISOSS-target are
described previously (41). H1299 cells were plated in
48-well plates in RPMI supplemented with 10% FBS
and grown to 40–60% conﬂuency overnight. pISOAS-
target and pISOSS-target (25 ng) were co-transfected with
0.2 ng pRluc-N2 (Perkin–Elmer) and siRNA duplexes
(5–50nM ﬁnal concentration) by simultaneous use of
0.5ml TransIT-LT1 (Mirus) and 0.5ml TransIT-TKO
(Mirus) according to manufacturer’s protocol. Luciferase
activity was measured 48h post-transfection using the
‘Dual-luciferase reporter assay system’ (Promega) accor-
ding to the manufacturer’s protocol on a FLUOstar lumi-
nometer (BMG labtech); ﬁreﬂy luciferase signals (sample)
were normalized to the renilla luciferase signals (transfec-
tion control).
RESULTS
We have evaluated the impact of 21 diﬀerent types of
chemical modiﬁcations on the activity and toxicity of a
standard 21–22 bp siRNA targeting eGFP using all com-
binations of 48 ASs and 45 SSs, thereby generating a total
of 2160 chemically diﬀerent siRNA duplexes (see Table 1
for AS and SS sequences). The modiﬁcations can be
broadly categorized into 20-substituted RNAs (OMe, F,
DNA, AEM, APM, EA, AP, CE, GE), 40-modiﬁed
RNAs (HM), Locked RNAs (LNA, ALN, ADA, PYR,
OX, AENA, CENA, CLNA) and RNAs with radical
modiﬁcations of the ribose sugar ring (UNA, ANA and
HNA; Figure 1; see ‘Material and Methods’ section for
full names). In brief, HeLa cells stably expressing eGFP
were transfected with siRNA duplexes (10nM ﬁnal con-
centration), and eGFP levels and cell viability were eval-
uated 72h post-transfection.
Modifications are well tolerated in theSS
We initially evaluated the impact of chemical modiﬁcation
on siRNA activity for all ASs and SSs in combination
with an unmodiﬁed RNA strand (SS and AS termed
W207 and W053, respectively). Modiﬁcations in the SS
were well tolerated, and even heavily modiﬁed SSs
supported knock down (KD) of eGFP levels to below
20% [e.g. HNA (GS2536), AEM (GS2543), APM
(GS2548), HM (W044), OMe/F (JC5) and LNA (W037)]
(Figure 2a and Table 1). Only in a few cases did introduc-
tion of multiple modiﬁcations result in reduced silencing
potency, as seen for ANA (GS2366), HNA (GS2370), an
additional UNA residue (W130) and full substitution
using DNA (W007) and DNA/LNA (W008, W009).
Bulky modiﬁcations were relatively well tolerated in the
SS [e.g. ADA (W069), AEM (GS2542, GS2543) and APM
(GS2547, GS2548)] as opposed to in the AS (see below).
Interestingly, thermodynamic stabilization of the siRNA
duplex by LNA could be achieved via SS modiﬁcation,
whereas a similar level of LNA modiﬁcation in the AS
abolished siRNA activity (compare SS W037 and AS
W010; Figure 2). This illustrates that the SS can be func-
tionalized by extensive modiﬁcations as long as the RNA
duplex structure is not grossly distorted.
Position-dependent tolerance for ASmodification
Modiﬁcation of the AS had a strong impact on siRNA
silencing activity with the most eﬃcient ASs being only
modestly modiﬁed (Figure 2b and Table 1). Accordingly,
extensive modiﬁcation reduced activity [e.g. HM
(JW1187), LNA (W010), ANA (GS2373) and HNA
(GS2540)] with the notable exception of the fully OMe/
F-substituted AS (JC10). We generally found bulky
modiﬁcations to be poorly tolerated in both the AS seed
region [e.g. ADA (W068), PYR (W096), Figure 2b; AEM
and APM in position 3, data not shown] and the 30-end
[e.g. ADA (W095), PYR (W097), AEM (GS2549), APM
(GS2544), OMe/EA (DO1002)], presumably due to helix
distortion or altered strand selection.
The AS seed region (positions 2–8) guides the initial
target recognition by RISC
  (42), and modiﬁcations in
this region should therefore inﬂuence silencing activity.
We found that single modiﬁcations in the seed region
were generally well tolerated for non-bulky groups that
do not strongly inﬂuence the thermodynamic stability
[e.g. HNA (GS2538, GS2539), ANA (GS2378), OMe-
(DHARM1), CENA (JC-F1, JC-F2, JC-F3) and HM
(JW1186), Figure 2b and Supplementary Figure 1]. In
contrast, modiﬁcations that stabilize the seed region,
such as LNA (Supplementary Figure 1) and AENA
(JC-A1, JC-A2 and JC-A3; Figure 2b) had a negative
eﬀect on silencing activity, presumably by altering strand
selection or seed–target interactions. The strongly destabi-
lizing UNA was better tolerated in the seed, but reduced
silencing activity when introduced near the 50-end where it
could destabilize AS–target interactions (Figure 2b, com-
pare W124 and W123, and Supplementary Figure 1). We
also found some sensitivity to modiﬁcation in the central
positions of the AS, which must be capable of perfect
base-pairing to the target to allow cleavage by Ago2 (7);
UNA (W126) and alternating OMe/F (JC10) were well
tolerated, while HNA and ANA impaired silencing
(GS2373 vs. GS2378 and GS2540, Figure 2b). As
expected, most modiﬁcations were well tolerated in the
AS 30-region [e.g. UNA (W125), HNA (GS2537), HM
(W042), LNA (W075) F/OMe (JC10)] and 30-overhang
[e.g. ANA (GS2372), HNA (GS2537), ALN (W047), EA
(JE1001), single HM (W059) and LNA (W006)], although
UNA- (W127), double HM- (W054) and LNA modiﬁca-
tions (W180) decreased silencing activity slightly
(Figure 2b).
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Name AS/SS Modiﬁcation eGFP levels
a Viability
a Sequence (50–30)
DHARM1 AS OMe 0.24 0.02 0.82 0.11 ACOMeUUGUGGCCGUUUACGUCGC
DO1001 AS OMe/EA 0.20 0.04 0.88 0.11 AOMeCUUGUGGCCGUUUACGUCGCEAU
DO1002 AS OMe/CE 0.49 0.06 1.01 0.24 AOMeCUUGUGGCCGUUUACGUCECGCU
GS2371 AS ANA 0.41 0.03 0.58 0.15 AANACANAUUGUGGCCGUUUACGUCGC
GS2372 AS ANA 0.11 0.01 0.59 0.08 ACUUGUGGCCGUUUACGUCGANACANAU
GS2373 AS ANA 1.12 0.08 0.73 0.19 ACUUGANAUGGANACCGANAUUUANAACGANAUCGANACU
GS2378 AS ANA 0.25 0.03 0.51 0.07 ACUANAUGUANAGGCCGUUUANAACGUANACGANACANAU
GS2537 AS HNA/DNA 0.19 0.02 0.57 0.04 ACUUGUGGCCGUUUACGUHNACHNAGHNATDNA
GS2538 AS HNA/DNA 0.21 0.04 0.48 0.07 ACHNAUUGUGGCCGUUUACGUHNACHNAGHNATDNA
GS2539 AS HNA/DNA 0.20 0.02 0.80 0.12 ACUHNAUGUGGCCGUUUACGUHNACHNAGHNATDNA
GS2540 AS HNA/DNA 0.63 0.08 0.71 0.12 ACHNAUUGUGGCHNACGUUUACGUHNACHNAGHNATDNA
GS2544 AS AEM/DNA 0.59 0.06 0.94 0.12 ACUUGUGGCCGUUUACGUAEMCAEMGTDNA
GS2549 AS APM/DNA 0.87 0.11 0.90 0.19 ACUUGUGGCCGUUUACGUAPMCAPMGTDNA
JC10 AS F/OMe 0.32 0.03 0.70 0.28 AFCOMeUFUOMeGFUOMeGFGOMeCFCOMeGFUOMeUFUOMeAFC
OMeGFUOMeCFGOMeCF
JC-A1 AS AENA 0.26 0.02 0.88 0.18 ACUAENAUGUGGCCGUUUACGUAENACGC
JC-A2 AS AENA 0.63 0.05 0.55 0.15 ACUUAENAGUGGCCGUUUACGUAENACGC
JC-A3 AS AENA 0.69 0.11 1.05 0.18 ACUAENAUAENAGUGGCCGUUUACGUAENACGC
JC-F1 AS CENA 0.10 0.02 0.87 0.17 ACUCENAUGUGGCCGUUUACGUCENACGC
JC-F2 AS CENA 0.18 0.05 0.80 0.19 ACUUCENAGUGGCCGUUUACGUCENACGC
JC-F3 AS CENA 0.19 0.04 1.08 0.12 ACUCENAUCENAGUGGCCGUUUACGUCENACGC
JC-S1 AS CLNA 0.12 0.01 0.80 0.12 ACUCLNAUGUGGCCGUUUACGUCLNACGC
JC-S2 AS CLNA 0.28 0.01 0.65 0.16 ACUUCLNAGUGGCCGUUUACGUCLNACGC
JC-S3 AS CLNA 0.31 0.04 0.86 0.08 ACUCLNAUCLNAGUGGCCGUUUACGUCLNACGC
JE1001 AS EA 0.13 0.01 0.62 0.17 ACUUGUGGCCGUUUACGUCGEACEAU
JH1001 AS AP 0.45 0.09 0.78 0.17 AAPCUUGUGGCCGUUUACGUCGCU
JW1186 AS HM/LNA 0.10 0.04 0.95 0.22 ACUUGTHMGGCCGUUUACGUCGLNACLNAU
JW1187 AS HM/LNA 0.76 0.13 1.01 0.25 ACTHMUGTHMGGCCGUUTHMACGTHMCGLNACLNAU
W006 AS LNA 0.09 0.01 0.49 0.11 ACUUGUGGCCGUUUACGUCGLNACLNAU
W010 AS LNA 0.54 0.08 0.67 0.07 ACTLNAUGTLNAGGCCGUUTLNAACGTLNACGLNACLNAU
W042 AS HM 0.18 0.03 0.44 0.09 ACUUGUGGCCGUUUACGUCHMGCHMU
W047 AS ALN 0.14 0.03 0.46 0.04 ACUUGUGGCCGUUUACGUCGCALNU
W053 AS 0.14 0.02 0.43 0.09 ACUUGUGGCCGUUUACGUCGC
W054 AS HM 0.33 0.06 0.69 0.12 ACUUGUGGCCGUUUACGUCTHMTHMU
W059 AS HM 0.18 0.02 0.72 0.14 ACUUGUGGCCGUUUACGUCGTHMU
W068 AS ADA/LNA 0.54 0.11 0.64 0.12 ACUUGTADAGGCCGUUUACGUCGLNACLNAU
W075 AS LNA 0.14 0.02 0.86 0.15 ACUUGUGGCCGUUUACGUCLNAGLNAC
W095 AS ADA/LNA 0.36 0.04 0.78 0.15 ACUUGUGGCCGUUUACGTADACGLNACLNAU
W096 AS PYR/LNA 0.38 0.06 0.52 0.15 ACUUGTPYRGGCCGUUUACGUCGLNACLNAU
W097 AS PYR/LNA 0.46 0.05 0.73 0.19 ACUUGUGGCCGUUUACGTPYRCGLNACLNAU
W106 AS OMe 1.11 0.12 0.73 0.31 AOMeCOMeUOMeUOMeGOMeUOMeGOMeGOMeCOMeCOMeGOMeUO
MeUOMeUOMeAOMeCOMeGOMeUOMeCOMeGOMeCOMeUOMe
W123 AS UNA/LNA 0.11 0.02 1.08 0.22 ACUUGUUNAGGCCGUUUACGUCGLNACLNAU
W124 AS UNA/LNA 0.16 0.05 0.89 0.22 ACUUNAUGUGGCCGUUUACGUCGLNACLNAU
W125 AS UNA/LNA 0.11 0.03 0.89 0.13 ACUUGUGGCCGUUUACGUUNACGLNACLNAU
W126 AS UNA/LNA 0.13 0.03 0.72 0.15 ACUUGUGGCCGUUNAUUACGUCGLNACLNAU
W127 AS UNA 0.26 0.05 0.66 0.12 ACUUGUGGCCGUUUACGUCGCUNAU
W128 AS UNA 0.56 0.11 0.80 0.23 ACUUNAUGUGGCCGUUUACGUCGCUNAU
W180 AS LNA 0.27 0.04 0.78 0.22 ACUUGUGGCCGUUUACGUCGLNACLNA
W209 AS LNA 1.18 0.23 0.88 0.22 ACTLNAUGTLNAGGCCGUUTLNAACGTLNACGLNACLNA
DO003 SS EA 0.10 0.01 0.67 0.10 GACGUAAACGGCCACAAEAGUUC
DO004 SS GE 0.12 0.01 0.62 0.05 GACGUAAACGGCCACAAGEGUUC
GS2332 SS HNA 0.15 0.01 0.55 0.12 GAHNACGUAAAHNACGGCCAHNACAAHNAGUUC
GS2366 SS HNA 0.40 0.06 0.65 0.60 GACGUHNAAAAHNACGGCCAHNACAAHNAGUUCTDNA
GS2368 SS ANA/DNA 0.11 0.02 0.71 0.11 GANAAANACGUAAACGGCCACAAGUUCTDNA
GS2369 SS ANA/DNA 0.10 0.01 0.64 0.18 GACGUAAACGGCCACAAGANAUANAUCTDNA
GS2370 SS ANA/DNA 0.31 0.03 0.73 0.22 GACGUANAAAAANACGGANACCAANACAAANAGUUCTDNA
GS2374 SS ANA 0.16 0.03 0.60 0.14 GACGUAAACGGCCACAAGUUANACANAU
GS2383 SS HNA 0.11 0.01 0.78 0.16 GACGUAAACGGCCACAAGUHNAUHNAC
GS2534 SS HNA/DNA 0.11 0.01 0.58 0.15 GHNAAHNACHNAGUAAACGGCCACAAGHNAUHNAUHNATDNA
GS2535 SS HNA/DNA 0.19 0.03 0.64 0.09 GACGUHNAAAAHNACGGHNACCAHNACAAGUUTDNA
GS2536 SS HNA/DNA 0.13 0.02 0.74 0.12 GACGUHNAAAAHNACGGHNACCAHNACAAGUHNAUHNATDNA
GS2542 SS AEM/DNA 0.11 0.01 0.66 0.15 GACGUAAACGGCCACAAGUAEMUAEMTDNA
GS2543 SS AEM/DNA 0.11 0.02 0.62 0.20 GACAEMGUAEMAAACAEMGGCCACAAGUAEMUAEMTDNA
GS2547 SS APM/DNA 0.12 0.01 0.64 0.18 GACGUAAACGGCCACAAGUAPMUAPMTDNA
GS2548 SS APM/DNA 0.17 0.02 0.61 0.08 GACAPMGUAPMAAACAPMGGCCACAAGUAPMUAPMTDNA
JC1 SS OX 0.11 0.01 0.63 0.20 GACGUAAACGGCCACAOXAGOXUUC
JC2 SS OX 0.13 0.02 0.81 0.19 GAOXCGOXUAAACGGCCACAAGUUC
(continued)
2870 Nucleic Acids Research, 2009, Vol. 37,No. 9In conclusion, modiﬁcation of the AS must take the
functional regions into account and should preferably be
restricted to the peripheral regions.
Identification ofhighly efficient siRNAs
We next investigated what chemical modiﬁcations could
enhance siRNA activity beyond that of an unmodiﬁed
siRNA duplex. We found two ASs (W006, JC-F1) and
six SSs (DO003, GS2369, JC1, W60, GS2542 and
GS2534) that performed signiﬁcantly better than unmodi-
ﬁed RNA when paired to an unmodiﬁed opposing strand
(Figure 2b). However, the eﬃciency of a SS in combina-
tion with an unmodiﬁed ASs (W053) does not necessarily
allow the prediction of its behaviour in combination with
other ASs. Our data from 2160 siRNAs provide valuable
insight into how chemically diﬀerent ASs and SSs can be
combined to generate highly modiﬁed and functional
siRNAs. We identiﬁed a total of 134 highly eﬃcient
(HE) siRNAs exhibiting enhanced silencing activity
compared with unmodiﬁed siRNA (Table 2 and
Supplementary Table 1). Interestingly, the most eﬃcient
siRNA (JW1186-W043) maintained stronger silencing
than unmodiﬁed siRNAs (W053-W207) even at a lower
concentration (3nM, Supplementary Figure 2), demon-
strating a higher potency that may prove important for
in vivo applications. Hereby our data show that several
types of chemical modiﬁcations can indeed enhance
siRNA activity beyond that of an unmodiﬁed siRNA
even in short-term cell-culture experiments.
Rescueof AS activity byoptimal SSs
We found only modestly modiﬁed ASs among the HE
siRNAs (Figure 2b; Tables 2 and 3), yet high levels of
siRNA modiﬁcation would be preferable for many
in vivo applications. Interestingly, the activity of most
ASs in our screen could be improved by combining the
ASs with speciﬁc ‘optimal’ SSs [Figure 3, compare
‘optimal SS’ (red line) and unmodiﬁed SS (W207, black
line)]; the most prominent eﬀect was seen for extensively
modiﬁed ASs [e.g. OMe (W106), LNA (W209) and ANA
Table 1. Continued
Name AS/SS Modiﬁcation eGFP levels
a Viability
a Sequence (50–30)
JC5 SS F/OMe 0.13 0.02 0.90 0.19 GFAOMeCFGOMeUFAOMeAFAOMeCFGOMeGFCOMeCFAOMeCFA
OMeAFGOMeUFUOMeCF
JE0007 SS EA 0.11 0.02 0.79 0.23 GACGUAAACGGCCACAAGUUEAC
JE0008 SS EA 0.11 0.02 0.66 0.13 GACGUAAACGGCCACAAGUEAUC
JE010 SS EA 0.13 0.01 0.84 0.15 GACGUEAAAACGGCCACAAGUEAUEAC
JW1104
b SS LNA GACGUAAACGGCCACAAGUTLNACLNAU
JW1106 SS LNA 0.12 0.01 0.80 0.16 GACLNAGUAAACLNAGGCCACLNAAAGUTLNACLNAU
JW1188 SS HM 0.15 0.02 0.62 0.15 GACGUAAACGGCCACAAGTHMTHMC
JW1189 SS HM 0.11 0.02 0.74 0.13 GACGTHMAAACGGCCACAAGTHMTHMC
W004+W179 SS LNA 0.13 0.03 0.71 0.17 GACLNAGUAAACLNAG + GCCLNAACLNAAAGUTLNACLNA
W007 SS DNA 0.69 0.09 1.06 0.19 GDNAADNACDNAGDNATDNAADNAADNAADNACDNAGDNAGDNACDNA
CDNAADNACDNAADNAADNAGDNATDNATLNACLNATDNA
W008 SS DNA/LNA 0.41 0.05 1.02 0.16 GDNAADNACLNAGDNATDNAALNAADNAADNACLNAGDNAGDNACLNA
CDNAADNACLNAADNAADNAGLNATDNATLNACLNATDNA
W009 SS DNA/LNA 0.71 0.06 1.04 0.17 GDNAALNACDNAGLNATDNAALNAADNAADNACDNAGLNAGDNACLNA
CDNAALNACDNAALNAADNAGLNATDNATLNACLNATDNA
W011 SS LNA 0.12 0.02 0.69 0.13 GACGTLNAAAACGGCCACAAGUTLNACLNAU
W013 SS LNA 0.19 0.03 0.95 0.13 GACLNAGTLNAAALNAACLNAGGCCACAAGUTLNACLNAU
W037 SS LNA 0.19 0.03 0.66 0.11 GACLNAGUAAACLNAGGCCLNAACLNAAAGUTLNACLNAU
W043 SS HM 0.11 0.02 0.60 0.14 GACGUAAACGGCCACAAGUTHMCHMU
W044 SS HM 0.12 0.02 0.67 0.17 GACHMGTHMAAACHMGGCCHMACAAGUTHMCHMU
W049 SS ALN 0.11 0.02 0.64 0.14 GACGUAAACGGCCACAAGUTALNCALNU
W050 SS ALN 0.12 0.02 0.68 0.15 GACALNGUAAACALNGGCCACALNAAGUTALNCALNU
W060 SS HM 0.10 0.01 0.70 0.11 GACGUAAACGGCCACAAGUUTHMU
W069 SS ADA/LNA 0.15 0.02 0.93 0.27 GACGTADAAAACGGCCACAAGUTADACLNAU
W129 SS UNA/LNA 0.20 0.04 0.79 0.22 GACGUUNAAAACGGCCACAAGUTLNACLNAU
W130 SS UNA/LNA 0.40 0.05 0.78 0.18 GACGUAAACCUNAGGCCACAAGUTLNACLNAU
W131 SS UNA 0.11 0.02 0.58 0.16 GACGUAAACGGCCACAAGUUUUNAU
W132 SS UNA 0.13 0.02 0.59 0.11 GACGUUNAAAACGGCCACAAGUUUUNAU
W181 SS LNA 0.14 0.02 0.65 0.18 GACLNAGUAAALNACGGCCLNAACLNAAAGUTLNACLNAU
W194 SS LNA 0.13 0.03 0.45 0.17 GACGUAAACGGCCACAAGUTLNACLNA
W207 SS 0.14 0.02 0.43 0.09 GACGUAAACGGCCACAAGUUC
The name, type of chemical modiﬁcation, eGFP levels, viability and sequence of the investigated ASs and SSs are given. The following modiﬁcation
abbreviations are used: 20-O-methyl (OMe), 20-ﬂuoro (F), 20-deoxy (DNA), 20-aminoethoxymethyl (AEM), 20-aminopropoxymethyl (APM),
20-aminoethyl (EA), 20-aminopropyl (AP), 20-cyanoethyl (CE), 20-guanidinoethyl (GE), 40-C-hydroxymethyl-DNA (HM), locked nucleic acid (LNA),
alfa-L-LNA (ALN), 20-N-adamant-1-ylmethylcarbonyl-20-amino-LNA (ADA), 20-N-pyren-1-ylmethyl-20-amino-LNA (PYR), oxetane-LNA (OX),
20,40-carbocyclic-ENA-LNA (CENA), 20,40-carbocyclic-LNA-locked nucleic acid (CLNA), unlocked nucleic acid (UNA), altritol nucleic acid (ANA)
20-deoxy-20-N,40-C-ethylene-LNA (AENA) and hexitol nucleic acid (HNA). The position of the modiﬁcation is shown in bold in the oligo sequence.
aeGFP levels and viability is given for the particular strand in combination with an unmodiﬁed opposing strand (SS=W207, AS=W053). eGFP
levels were normalized to cells transfected with siEGFP mismatch control (Dharmacon, Dharmacon, Inc.) and viability was normalized to cells
treated with transfection reagent alone.
bThe JW1104 SS is not included in the large-scale siRNA screen but in subsequent analysis only.
Nucleic Acids Research,2009, Vol.37, No. 9 2871(GS2373)]. The activity of certain ASs was improved by
several optimal SSs (e.g. W097, GS2549, JC-A2 and
GS2544) whereas other ASs were only rescued by one or
few SSs (e.g. W209 by GS2542, JC-A3 by W194 and W106
by GS3543, Figure 3 and Supplementary Table 1).
Conversely, certain ASs allowed the use of heavily modi-
ﬁed SSs that failed to support RNAi when combined with
an unmodiﬁed AS; the fully LNA/DNA substituted SS
W009, produced a potent  80% KD in combination
with the UNA-modiﬁed AS W123 but gave only a 30%
KD in combination with unmodiﬁed AS W053 (Supple-
mentary Table 1). These observations imply that the
reduced activity often observed upon extensive siRNA
modiﬁcation can be compensated by careful matching of
speciﬁcally modiﬁed SSs and ASs. However, our data also
identiﬁes SSs that act as more ‘general optimal SSs’ to
improve the performance of many ASs and are therefore
broadly applicable in siRNA design. In particular, SSs
modiﬁed in the 30-overhang by UNA and HM (W131
and W043, respectively) or destabilized in the 30-end by
EA and OX (DO003 and JC1, respectively) produced a
strong KD in combination with many ASs (Table 3 and
Figure 3).
Strategies forenhancing siRNA activity
The HE siRNA duplexes were found to harbour modiﬁca-
tions either in the 30-overhang (e.g. W006, JE1001,
GS2372, W043, W047, W060, W131), within the siRNA
body (e.g. JC-F1, DO003, JC-S1, JC1, GS2369) or in
both regions (e.g. GS2383, JW1189, GS2542, GS2534)
(Tables 2 and 3), and we therefore speculated that two
mechanisms were responsible for enhancing siRNA activ-
ity: (i) Modiﬁcation of the siRNA body to introduce ther-
modynamic asymmetry to favour AS incorporation into
RISC. (ii) Modiﬁcation of SS and AS 30-overhangs to
enhance serum stability or aﬀect strand selection by RISC.
Destabilization of SS3’-ends enhances silencing efficiency
Given that strand selection during RISC loading, and
thereby AS activity, is dependent on the thermodynamic
proﬁle of the siRNA duplex we investigated the impact of
modiﬁcations on thermodynamic asymmetry. The chemi-
cal modiﬁcations used in this study have both stabilizing
(OMe, F/OMe, HNA, ANA, ALN, LNA) and destabi-
lizing (DNA, AEM, APM, OXE, EA, AP, CE, UNA)
properties. We found 15 of the 20 most eﬃcient siRNA
Figure 1. Structural overview of chemical modiﬁcations investigated.
2872 Nucleic Acids Research, 2009, Vol. 37,No. 9duplexes to have chemical modiﬁcations favouring AS
incorporation by altering the thermodynamic proﬁle.
W123 contained a 50-end destabilizing UNA, whereas
JC-F1 and JC-S1 contained CENA and CLNA resulting
in stabilization of the AS 30-end (see Tables 2 and 3 and
Supplementary Table 1). Nearly a third of the HE siRNAs
(38/134) contained these three ASs suggesting that altering
the thermodynamic asymmetry through AS modiﬁcation
is a major determinant of siRNA activity.
A similar trend was found among the HE SSs; the
30-end OX-destabilized JC-1 and the 30-end EA destabi-
lized DO003 improved the performance of most ASs
(Figure 3, orange and green, respectively, and Figure 4a,
columns 1, 2, 13,14) and resulted in an average 25%
improvement in activity for 22 and 23 ASs, respectively
(Table 3). Furthermore, JC1 and DO003 were highly
represented among the 134 HE siRNAs and among the
top three SSs for each AS (Table 3). Conversely, we
found both SS 30-end stabilization (e.g. GS2369 and
GS2383; Figure 4a, columns 11, 23 and 12, 24) and SS
50-end destabilization (e.g. JC2 and W129; Figure 4a,
columns 9, 21 and 10, 22) to negatively inﬂuence the acti-
vity of many ASs. The stabilization of the SS 50-end should
improve siRNA performance, and moderate 50-end stabi-
lization (e.g. GS2368; Figure 4a, columns 4, 16) did
improve the performance of most ASs; however more sta-
bilizing modiﬁcations (e.g. multiple HNAs (GS2534;
Figure 4a, columns 5, 17), single and extensive LNA
modiﬁcations [(W011 and W013; Figure 4a, columns 6,
18 and 7, 19)] impaired silencing. This suggests that,
although favouring AS selection, extensive thermody-
namic stabilization of an siRNA duplex is detrimental to
silencing activity. In accordance, the activity of stabilized
ASs (e.g. W106, W209 and GS2373) was enhanced both by
the 30-end destabilized SSs (DO003 and JC1) and by the
50-end destabilized JC-2 although this SS should disfavour
AS incorporation into RISC based on thermodynamic
asymmetry (Figure 3 and Supplementary Table 1). This
highlights that siRNA thermodynamic stability should
fall within a range compatible with the components
of the RNAi machinery, and that both siRNA thermody-
namic asymmetry and stability are critical parameters to
Figure 2. Silencing activity of chemically modiﬁed SSs and ASs. HeLa-eGFP were transfected with the indicated siRNAs (10nM concentration) and
eGFP levels were evaluated 72h post-transfection. (a) Silencing activity of modiﬁed SSs in combination with the unmodiﬁed AS, W053. (b) Silencing
activity of modiﬁed ASs in combination with the unmodiﬁed SS, W207. Colour-code: 20-OH substituted oligos (blue), 40-modiﬁed oligos (pink),
20-locked oligos (green) and ribose ring modiﬁed oligos (orange).
Nucleic Acids Research,2009, Vol.37, No. 9 2873consider during siRNA design. Based on our screen, rela-
tive destabilization of the SS 30-end (using DO003 and
JC1) represented the more reliable strategy to improve
siRNA performance unless high stability of the duplex is
speciﬁcally required.
Modification of3’-overhangs influences siRNA activity
The observation that several highly eﬃcient siRNAs (e.g.
W006-W060, W006-W043 and W006-W131) are modiﬁed
in the 30-overhangs only, highlights the importance
of overhangs for silencing activity (Figure 2, Tables 2
and 3). In fact, ASs modiﬁed exclusively in the
30-overhang by LNA (W006), EA (JE1001), ALN
(W047) and ANA (GS2372) were found in half (66/134)
of the HE siRNAs. The impact of 30-overhang modiﬁca-
tion was highly chemistry dependent; the UNA- (W127),
LNA- (W180) and HM-modiﬁed (W054) ASs showed a
signiﬁcantly reduced silencing activity whereas ASs modi-
ﬁed by ANA (GS2372), EA (JE1001) and ALN (W047)
were equally eﬃcient to unmodiﬁed RNA (W053)
(Figure 2b). Interestingly, the LNA-modiﬁed overhang
in W006 (50-LNA-LNA-RNA-30) containing an additional
30-RNA residue resulted in signiﬁcantly improved silen-
cing (Figure 2b; see the Discussion section below).
We speculated that the inﬂuence of 30-overhang modiﬁ-
cations could result from diﬀerences in siRNA serum sta-
bility; however, no clear correlation between stability and
silencing activity was observed for overhang-modiﬁed
siRNAs (Figures 2 and 5 and data not shown). Instead
modiﬁcation of the 30-overhang was found to inﬂuence
strand selection, as modiﬁcations disfavoured in the AS
30-overhang [e.g. HM (W054), UNA (W127), LNA
(W180); Figures 2b and 4b] were found to favour AS selec-
tion when incorporated into SS 30-overhangs [HM
(W043), LNA (W194) and UNA (W131); Figure 4b]. In
detail, the silencing activity of the LNA-modiﬁed AS
W180 (Figure 4b, column 9) was enhanced to a level indis-
tinguishable from unmodiﬁed siRNA (Figure 4b, column
5) when paired to a SS with disfavoured overhangs, such
as LNA (W194), UNA (W131) and HM (W043)
(Figure 4b, columns 10–12). Similar SS 30-overhang eﬀects
were seen for the UNA-modiﬁed AS W127 (Figure 4b,
columns 13–16) and HM-modiﬁed AS W054 (Figure 4b,
columns 17–20). The HM modiﬁcation was particularly
strongly disfavoured as the HM-modiﬁed W054 was a
signiﬁcantly poor AS (Figure 4b, column 17), while the
Table 3. Highly eﬃcient SSs and ASs
Strand
name
AS/
SS
Sequence (50–30) Percentage in
HE siRNAs/
top 3 siRNAs
# impr. ASs/
avr. impr.
(%)
Remark
DO003 SS GACGUAAACGGCCACAAEAGUUC 7/15 23/27 Destabilized 30-end favours AS selection
JC1 SS GACGUAAACGGCCACAOXAGOXUUC 7/10 22/25 Destabilized 30-end favours AS selection
W043 SS GACGUAAACGGCCACAAGUTHMCHMU 6/13 25/17 Disfavoured 30-overhang favours AS selection
W131 SS GACGUAAACGGCCACAAGUUUUNAU 7/11 21/13 Disfavoured 30-overhang favours AS selection
GS2383 SS GACGUAAACGGCCACAAGUHNAUHNAC 6/7 17/26 Disfavoured 30-overhang favours AS selection
JW1189 SS GACGTHMAAACGGCCACAAGTHMTHMC 6/5 14/21 Disfavoured 30-overhang favours AS selection
W004+W179 SS GACLNAGUAAACLNAG+
GCCLNAACLNAAAGUTLNACLNA
2/4 4/115 Stabilizing SS for highly modiﬁed ASs
W006 AS ACUUGUGGCCGUUUACGUCGLNACLNAU 24/– – HE ASs, favoured 50-overhang
JE1001 AS ACUUGUGGCCGUUUACGUCGEACEAU 15/– – HE ASs, favoured 50-overhang
W123 AS ACUUGUUNAGGCCGUUUACGUCGLNACLNAU 13/– – HE ASs, favoured 50-overhang
GS2372 AS ACUUGUGGCCGUUUACGUCGANACANAU 9/– – HE ASs, favoured 50-overhang
JC-S1 AS ACUCLNAUGUGGCCGUUUACGUCLNACGC 9/– – HE ASs, thermodynamically asymmetric
W047 AS ACUUGUGGCCGUUUACGUCGCALNU 9/– – HE ASs, favoured 50-overhang
JW1186 AS ACUUGTHMGGCCGUUUACGUCGLNACLNAU 8/– – HE ASs, favoured 50-overhang
JC-F1 AS ACUCENAUGUGGCCGUUUACGUCENACGC 7/– – HE ASs, thermodynamically asymmetric
The name, sequence, statistical performance and remarks are given for the most eﬃcient SSs and ASs. ‘Percentage in HE siRNA’ refers to the
percentage of the 134 HE siRNAs containing the particular AS/SS. ‘Percentage in top 3 siRNAs’ refers to the summed representation of the
particular SS among the three most eﬃcient SSs for each AS (in %). ‘#impr. ASs/avr. improvement’ refers to the number and average improvement
(%) of ASs whose activity is signiﬁcantly enhanced by the particular SS as compared with the unmodiﬁed SS (W207). Modiﬁcations are highlighted
in bold in the sequences.
Table 2. Highly eﬃcient siRNA duplexes
AS SS eGFP levels Viability Rank
JW1186 W043 0.06 0.01 0.62 0.12 1
W123 W131 0.06 0.02 1.05 0.08 2
JW1186 W131 0.06 0.01 0.66 0.20 3
JC-S1 DO003 0.06 0.01 0.65 0.13 4
W123 W043 0.06 0.01 0.89 0.20 5
GS2372 GS2383 0.06 0.01 0.60 0.15 6
JC-F1 W131 0.07 0.01 0.64 0.17 7
W123 JW1189 0.07 0.01 0.92 0.25 8
GS2372 DO003 0.07 0.01 0.47 0.14 9
JC-S1 JC1 0.07 0.01 0.62 0.13 10
W053 W207 0.09 0.01 0.73 0.14 380
Dharmacon – – 1.00 0.07 0.78 0.10 –
Mock – 1.09 0.04 1.00 0.15 –
W006 W004+W179 0.09 0.01 0.57 0.16 35
JW1186 W004+W179 0.12 0.02 0.90 0.10 238
W123 W037 0.13 0.02 1.01 0.18 276
W006 W037 0.13 0.02 0.65 0.20 326
JC10 W004+W179 0.32 0.06 0.88 0.11 983
W010 W004+W179 0.34 0.07 0.46 0.27 1028
Relative silencing activity (eGFP levels), viability (# nuclei) and activity
ranking of the most eﬃcient siRNA duplexes. Upper panel: top 10
performing siRNA duplexes. Lower panel: selected siRNAs with high
activity and LNA modiﬁcations in the SS for enhanced serum stability.
The unmodiﬁed siRNA (W053-W207) is highlighted in bold.
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eﬀect on ASs with disfavoured overhangs (Figure 4b,
columns 8, 12, 16, 29). This suggests that HM-modiﬁed
overhangs may be more strongly disfavoured than
UNA- (W131) and LNA-modiﬁed (W194) SS and can
therefore be broadly used in SS design to favour
AS-strand selection.
Modified overhangs alter strand selection by RISC
To further investigate the impact of 30-overhang modiﬁca-
tions on altered strand selection, we evaluated the activity
of both strands in the siRNA duplex using reporters con-
taining a perfect target site for either the SS or AS down-
stream of a luciferase open reading frame (Figure 4d). We
expected disfavoured modiﬁcations in the AS 30-overhang
[LNA (W180), UNA (W127), HM (W054)] to increase
incorporation of the unmodiﬁed SS (W207) into RISC
 ,
thereby leading to higher SS silencing activity. Indeed, the
modest silencing eﬀect of the SS (W207) in an unmodiﬁed
duplex (5nM concentration) was signiﬁcantly increased
when combined with an AS with a disfavoured overhang
(Figure 4c, compare column 2 with 4, 6, 8). We therefore
suggest that disfavoured modiﬁcations in 30-overhangs can
be used to favour the incorporation of opposing strands,
irrespective of the thermodynamic asymmetry of the
siRNA duplex.
Intriguingly, we found the AS W006 to be signiﬁcantly
more eﬃcient than an unmodiﬁed AS (W053) when paired
to W207 suggesting the 3-nt 50-LNA-LNA-RNA-30 over-
hang motif to be favoured for RISC loading even over the
natural RNA–RNA 30-overhang (Figures 2b and 4b). In
agreement, a SS (JW1104) with the 50-LNA-LNA-RNA-30
overhang motif exhibited signiﬁcantly enhanced activity
compared with the unmodiﬁed SS (W207) (Figure 4c,
compare columns 2 and 10) and a similar eﬀect was
obtained when combining JW1104 with the disfavoured
ASs W180 (LNA), W127 (UNA) and W054 (HM)
(Figure 4c, compare columns 4, 6, 8 and 12, 14, 16). We
found other highly eﬃcient ASs modiﬁed exclusively in the
30-overhang by EA (JE1001), ANA (GS2372) and ALN
(W047) (Table 3) to be favoured during RISC loading as
Figure 3. Optimal SSs enhance the activity of ASs. Relative eGFP expression of HeLa-eGFP cells transfected with all investigated ASs (X-axis, ASs
name given in bold) in combination with all 45 SSs (represented by grey dots) or with selected SSs (coloured triangles/lines). The activity of most ASs
in combination with the unmodiﬁed SS, W207 (represented by black triangles/line) can be enhanced in combination with a speciﬁc, optimal SS for
each AS (red triangles/line; name of the particular optimal SS for each AS is underlined). Furthermore the activity of many ASs is enhanced by the
thermodynamically asymmetric SSs, DO003 (dark green triangles) and JC1 (orange triangles), as well as the 30-overhang modiﬁed SSs, W043 (dark
blue triangles) and W131 (light blue triangles). In contrast, the thermodynamically asymmetric SS, JC2, decreases the activity of many ASs (purple
triangles).
Nucleic Acids Research,2009, Vol.37, No. 9 2875they lowered the activity of the opposing SS (W207) as
compared with the unmodiﬁed AS W053 (Supplementary
Figure 3). Consequently, favoured overhangs such as the
50-LNA-LNA-RNA-30 motif and others can be broadly
utilized to favour AS incorporation into RISC
 , thereby
enhancing siRNA potency.
Enhancing siRNA serum stability by chemical modification
The identiﬁcation of highly nuclease-resistant siRNAs is a
key concern for in vivo applications and great eﬀorts have
been applied to enhance stability by chemical modiﬁcation
(14,16,22,43). Like other studies, we ﬁnd siRNA serum
stability to be positively correlated with the level of
RNA modiﬁcation for most chemistries. While substitu-
tion of 30-overhangs led to a modest increase in serum
stability (e.g. UNA, ALN, HM, LNA, ANA; Figure 5a,
left panel), partial or full modiﬁcation of the siRNA body
led to eﬃcient stabilization (OMe/F, OMe, DNA/LNA
LNA; Figure 5a, right panel). Although a large number
of substitutions within an siRNA does indeed enhance
stability, highly modiﬁed siRNAs generally displayed
poor silencing. Fully OMe/F-substituted siRNAs have
previously been reported to be both highly stable and
more potent than standard siRNAs (30); however, in
our hands a similar siRNA (JC5-JC10) exhibited high sta-
bility, but produced a very modest 26% KD (Figure 5a
and Supplementary Table 1). This highlights the impor-
tance of identifying other strategies for siRNA stabiliza-
tion that support high silencing activity. Interestingly,
we found that LNA-mediated stabilization of selected
positions within the siRNA duplex led to similar or
even enhanced stability as compared with fully sub-
stituted duplexes (Figure 5a, compare W010-W037,
W010-W004-W179, JC10-W037 with JC5-JC10 and
W106-W009). In fact, the partially LNA-modiﬁed
W006-W037 and W010-W004-W179 exhibited higher
Figure 4. Improvement of siRNA performance by introduction of additional thermodynamic asymmetry and modiﬁcation of 30-overhangs. (a) The
performance of ASs (exempliﬁed by the representative ASs DO1001 and JC-S3) can be modiﬁed by altering the overall thermodynamic proﬁle of the
siRNA duplex by introduction of chemical modiﬁcation in the SS. (b) The siRNA activity is inﬂuenced by the nature of the AS and SS 30-overhangs.
ASs modiﬁed in the 30-overhang by LNA, UNA and HM have signiﬁcantly lower activity than unmodiﬁed and LNA-modiﬁed AS in combination
with the RNA SS (blue). This loss of activity can be partly rescued by using SSs with the disfavoured overhangs LNA, UNA or HM. (c) The LNA-
LNA-RNA motif is a favoured 30-overhang motif. The silencing activity of both the AS (on the AS-target, blue) and SS (on the S-target, red) is
shown for the unmodiﬁed, HM-, UNA- and LNA-modiﬁed ASs in combination with unmodiﬁed and LNA-modiﬁed SSs. (d) Overview of the
luciferase reporters used to evaluate the silencing activity of both the AS (denoted ‘AS-target’) and SS (denoted ‘SS-target’).
2876 Nucleic Acids Research, 2009, Vol. 37,No. 9stability than the fully OMe/F-substituted JC5-JC10,
while retaining a potent 87% and 66% KD activity,
respectively (Table 2 and Figure 5a). Moreover, we
found that the sisiRNA design (41) that utilizes an
LNA-stabilized segmented SS (W004+W179) may be
broadly applied to introduce LNA-stabilization with
minor impact on activity. The sisiRNA constructs
W010-W004-W179 and JC10-W004-W179 retained both
high silencing activity and serum stability when modiﬁed
extensively with LNAs, whereas an intact LNA-modiﬁed
SS (W037) was detrimental to siRNA activity
(W010-W037 and JC10-W037, Figure 5). In fact, the
sisiRNA design allowed the LNA-stabilization of several
diﬀerentially modiﬁed ASs without major loss of silencing
activity (Figure 5b). This implies that siRNA stabilization
is preferentially achieved by introducing few LNA modi-
ﬁcations, preferentially using the sisiRNA design, rather
than generating fully substituted duplexes. Furthermore,
selected modiﬁcations allow further functionalization of
the siRNA duplex through modiﬁcation of the remaining
nucleotide positions.
Reducing siRNA toxicity throughchemical modification
Chemical modiﬁcations have previously been shown to
aﬀect the toxicity of siRNAs (44) and we therefore
Figure 5. Enhancing serum stability of siRNAs with minor loss of activity. (a) The biostability of modiﬁed siRNAs was evaluated by incubation in
80% FBS. While a low level of chemical modiﬁcation results in only modest increase in stability (left panel), more extensive and full substitutions
result in dramatically improved siRNA stability (right panel). The incubation time is given in hours (h). (b) The eGFP levels of cells transfected
with modiﬁed ASs paired with either unmodiﬁed SS (W207), LNA-modiﬁed segmented SS (W004+W179), fully OMe/F substituted SS (JC5) and
LNA-modiﬁed SS (W037) are given. The segmented LNA-modiﬁed SS (W004+W179) generally prevented the loss in activity imposed by the
LNA-modiﬁed unsegmented SS (W037).
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72h (as number of nuclei per well relative to mock trans-
fections). The majority of modiﬁed SSs resulted in a
similar high degree of viability in combination with
unmodiﬁed RNA AS whereas the viability varied more
dramatically among the modiﬁed ASs in combination
with the RNA SS (Table 1). We found cell viability to
correlate with siRNA potency for the majority of ASs
(Supplementary Figure 4) with only a few non-functional
siRNAs resulting in low cell viability (Figure 6). This sug-
gests that the observed siRNA toxicity arises from eﬃcient
ASs interfering with the endogenous RNAi pathway.
Indeed, plotting the relative eGFP levels versus relative
viability allowed us to identify distinct subgroups of
ASs; the unmodiﬁed W053, and the LNA-modiﬁed
W006 displayed high silencing potency and moderate
cell viability (Figure 6, yellow and purple triangles, respec-
tively), the OMe- (W106) and heavily LNA- (W209) modi-
ﬁed ASs had poor activity and high viability (Figure 6,
light blue and brown triangles, respectively), while the
HNA-modiﬁed GS2538 had high activity and very low
viability (Figure 6, red triangles). Interestingly, silencing
activity and viability of particularly the UNA- (W123) but
also the HM- (JW1186) modiﬁed ASs were both high in
combination with most SSs (Figure 6, green and dark blue
triangles, respectively). Hereby our data shows that
although most potent siRNAs cause reduced viability, it
is possible to generate highly potent and non-toxic
siRNAs by selecting particular chemical modiﬁcations.
DISCUSSION
Optimization of siRNA performance by chemical modi-
ﬁcation has been addressed in several studies
(14–18,22,23,31,41); however, in most cases cross-study
comparisons of chemistries are diﬃcult. In the present
study, we have directly compared the impact of 21 types
of chemical modiﬁcations on siRNA activity and cell via-
bility using 2160 chemically diﬀerent siRNA duplexes,
thus providing unique insight into the ways speciﬁc che-
mistries can be combined to generate siRNAs with supe-
rior properties. As a result we have identiﬁed 134 siRNA
duplexes displaying higher silencing activity than standard
siRNAs. The majority of these highly eﬃcient siRNAs are
only modestly modiﬁed, and especially the AS exhibited a
limited and position-dependent tolerance for modiﬁcation.
This is expected as the AS must be bound at the 30-end by
Ago2 during RISC loading (42,45), guide initial target
interactions in the seed region (positions 2–8) (42,46,47)
and be perfectly base paired in the central region to sup-
port Ago2-mediated target cleavage (7,42). Modiﬁcation
of the SS was generally well tolerated, and this strand
Figure 6. Identiﬁcation of highly eﬃcient siRNAs with low toxicity. Scatter plot showing target cell viability versus eGFP expression (siRNA
activity) for all tested siRNAs (grey dots) and for selected ASs in combination with all 45 SS (coloured dots). Silencing activity correlates with
toxicity for most siRNAs. The highly active, unmodiﬁed (W053, yellow triangles), HNA- (GS2538, red triangles) and LNA- (W006, purple triangles)
modiﬁed ASs have high activity and poor viability, whereas heavily LNA- (W209, light brown triangles) and OME- (W106, light blue triangles)
modiﬁed ASs have poor activity, but high viability. In contrast, the UNA- (W123, green triangles) and HM- (JW1186, dark blue triangles) modiﬁed
ASs have both high activity and viability.
2878 Nucleic Acids Research, 2009, Vol. 37,No. 9would therefore be useful as an entry route for extensive
modiﬁcations in the siRNA duplex.
Our data highlights that improvement of siRNA perfor-
mance by chemical modiﬁcations should focus primarily
on ensuring preferential loading of the intended AS into
RISC
 , as chemical modiﬁcations aﬀecting the thermody-
namic asymmetry of the siRNA duplex or the recognition
of 30-overhangs were the major contributors to improved
silencing activity in our screen. Previous results have
demonstrated the strand containing the least stable
50-end to be preferentially utilized as the guide strand in
RISC
  (5,6). In agreement, we found chemical modiﬁca-
tions leading to relative destabilization of the AS 50-end to
be highly represented among the most potent siRNA
duplexes. In contrast, strong destabilization of the AS
seed region reduces siRNA silencing activity presumably
by weakening its interactions with the target mRNA. AS
selection can also be favoured by incorporation of stabi-
lizing modiﬁcations in the SS 50-end or AS 30-end, and
accordingly previous studies have successfully incorpo-
rated LNA into SS 50-ends to favour AS selection
(17,23). Although our results support this observation,
we found a large increase in thermostability to reduce
siRNA activity, and we therefore suggest favouring AS
selection by destabilization of the SS 30-end, unless high
stability of the siRNA duplex is speciﬁcally required.
Previous studies have given little attention to the choice
of siRNA 30-overhangs, and chemical modiﬁcation of
30-overhangs appears to be generally well tolerated [this
study and (18,41,48)]. Interestingly, our study shows that
chemical modiﬁcation of siRNA 30-overhangs can be uti-
lized to favour AS selection during RISC loading irrespec-
tive of the thermodynamic asymmetry of the duplex.
We have identiﬁed 30-overhang motifs that are either
favoured (50-LNA-LNA-RNA-30 and others) or disfa-
voured (50-RNA-HM-30 and 50-RNA-UNA-RNA-30)b y
the RNAi machinery, and we therefore propose the incor-
poration of disfavoured overhangs in the SS and favoured
overhang in the AS for optimal siRNA performance.
For many applications, particularly in vivo, extensive
modiﬁcation is required to enhance siRNA stability or
support delivery strategies. Improved resistance towards
nucleases has been a primary goal of siRNA modiﬁcation
and several highly stabilized siRNAs have already been
developed, albeit often at the expense of activity [this
study and (14,16,22,49)]. Interestingly, we found that the
poor activity of many modiﬁed ASs can be partially res-
cued by combination with an ‘optimal’ SS (Figure 3), sug-
gesting that heavily modiﬁed ASs are incompatible with
recognition by the RNAi machinery rather than incompe-
tent for target cleavage. Hereby our data provides unique
insight into synergistic eﬀects between chemistries that
maximize the level of modiﬁcation and minimize the loss
of activity.
Chemical modiﬁcation of siRNA overhangs could pro-
vide protection against exonucleases and was found to
elicit a modest increase in serum stability, while resistance
towards endonucleases was achieved by substituting mul-
tiple positions in the siRNA body (Figure 5). We evalu-
ated the serum stability of the heavily modiﬁed,
yet functional siRNAs in our screen and found that
partially LNA-substituted JC10-W004-W179 and W010-
W004-W179 exhibited stabilities similar to highly and
fully modiﬁed siRNAs. This suggests that enhancement
of siRNA stability need not focus on substituting all
positions of the siRNA duplex, but can be restricted to
few selected positions. We speculate that resistance
towards endonucleases could be inﬂuenced by the thermo-
dynamic stability of the duplex; in this regard, the segmen-
ted sisiRNA design (Table 1: SS W004-W179) provides a
convenient way of introducing highly stabilizing LNA
modiﬁcations in a conﬁguration well tolerated by the
RNAi machinery (41). Importantly, this design allows
the generation of more functionalized siRNA duplexes
in which other positions could be modiﬁed to minimize
siRNA oﬀ-target eﬀects and toxicity or favour delivery
strategies. It is noteworthy that extensive stabilization of
siRNAs should only be applied when explicitly needed,
e.g. upon injections of naked siRNA in vivo. When using
siRNAs shielded by transfection reagents in cell culture or
even in vivo, chemical modiﬁcation should primarily aim
at maximizing silencing activity as exempliﬁed by the 134
HE siRNAs identiﬁed in this study.
It is interesting that the most highly active siRNA
duplexes, including the unmodiﬁed siRNA (W053-
W207), have a negative impact on cell viability compared
with mock transfections. Only 26 out of 134 highly eﬃ-
cient siRNAs resulted in viabilities indistinguishable from
mock controls, and among these, the UNA- (W123) and
HM- (W1186) modiﬁed ASs were represented 15 and 6
times, respectively, indicating that very few ASs are both
highly active and non-toxic. SiRNA toxicity may have
several sources ((50–52) but we suspect that highly active
siRNA duplexes interfere with endogenous RNAi path-
ways as most non-functional siRNAs in our screen are
non-toxic. This type of competition between exogenous
RNAi substrates and endogenous miRNAs has been
observed both in cell culture (53) and in vivo (54).
Alternatively, the toxicity may arise from oﬀ-target eﬀects
due to a miRNA-like behaviour on mRNAs with 6–7nt
matches with the AS/SS seed region (25). Interestingly, the
eﬃcient, non-toxic ASs W123 and JW1186 both contain
modiﬁcations within their seed region, and we speculate
that this may lower the potential for oﬀ-target eﬀects by
destabilizing miRNA-like interactions. Indeed, recent
work has demonstrated that siRNA oﬀ-targeting can be
minimized by a slight destabilization of the siRNA–target
interaction by the introduction of DNA in the AS
seed (55).
In summary, our results have allowed us to formulate
the following guidelines for enhancing siRNA activity
through chemical modiﬁcations:
(1) siRNA overhangs can be chemically modiﬁed to
favour AS incorporation into RISC
 ; the SS should
contain disfavoured overhangs such as UNA, HM
and LNA-LNA, whereas the AS should contain
favoured overhang motifs such as LNA-LNA-RNA.
(2) In order to favour AS incorporation into RISC
  the
siRNA duplex should preferably be destabilized by
modiﬁcations in the SS 30-end rather than stabilized
in the SS 50-end. Additionally, the AS should not
Nucleic Acids Research,2009, Vol.37, No. 9 2879contain strongly destabilizing/stabilizing/bulky
modiﬁcations within the 50-end of the seed region.
(3) The use of single UNA and HM modiﬁcations in the
AS seed region increases cell viability upon siRNA
transfection.
(4) Enhanced serum stability can be obtained by selec-
tive thermodynamic stabilization of a few positions
rather than full substitution of the entire siRNA
duplex. The sisiRNA design may provide a conve-
nient way to introduce strong LNA stabilization
for many types of AS.
As demonstrated here, using the above guidelines to com-
bine various types of chemical modiﬁcations will lead to
the generation of superior siRNAs with high activity, high
stability and low toxicity.
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